Cyclophosphamide-glucocorticoids versus lenalidomide-dexamethasone as treatment for multiple myeloma at first relapse after autologous stem cell transplantation – a retrospective analysis

Autor: Russell Sterrett, Amarilis Figueiredo, Ranjeeta Mallick, Natasha Kekre, Harold Atkins, Arleigh McCurdy

Publikováno v: Hematology, Transfusion and Cell Therapy, Vol 43, Iss 4, Pp 437-442 (2021)

There have been significant improvements in therapeutic options for relapsed multiple myeloma (MM) over the past two decades, with many novel agents including proteasome inhibitors, immunomodulatory agents, and more recently monoclonal antibodies dem

Externí odkaz: https://doaj.org/article/855b6e849f604315b0e9b1d6256a2e6b

The impact of multiple myeloma induction therapy on hematopoietic stem cell mobilization and collection: 25-year experience

Autor: Harold L. Atkins, Amarilis Figueiredo, Natasha Kekre, Rashed Albacker, Rabih Kassis, Arleigh McCurdy

Publikováno v: Hematology, Transfusion and Cell Therapy, Vol 41, Iss 4, Pp 285-291 (2019)
Hematology, Transfusion and Cell Therapy
Hematology, Transfusion and Cell Therapy, Volume: 41, Issue: 4, Pages: 285-291, Published: 25 NOV 2019

While first-line induction therapy for patients with multiple myeloma has changed over the years, autologous hematopoietic stem cell transplantation still plays a significant role, improving both depth of response and progression-free survival of mye

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9102266bc0ac74ba5774834deb3ca4f2
http://www.sciencedirect.com/science/article/pii/S2531137919300884

A Comparison of Cyclophosphamide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma

Autor: Amarilis Figueiredo, Ranjeeta Mallick, Harold Atkins, Natasha Kekre, Andrea Kew, Arleigh McCurdy

Publikováno v: Blood. 128:4519-4519

Introduction Cyclophosphamide, bortezomib, and dexamethasone (CyBor-D) is considered a standard induction regimen for transplant eligible patients with newly diagnosed multiple myeloma (MM) based primarily on phase 2 data. It has not been directly co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d9be8767af568b469431f57a7bccce92
https://doi.org/10.1182/blood.v128.22.4519.4519